Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jardiance's Label Expansion Will Change Diabetes Management

Executive Summary

US approval of the first cardiovascular label expansion for an anti-diabetic medicine will mark a shift in disease management, says Datamonitor Healthcare analyst Kevin Shannon.

Advertisement

Related Content

Keeping Track: US FDA Accepts Ertugliflozin, Extends Reviews Of Abaloparatide, New Keytruda Claim
Jardiance Outcomes-Based Contracting Push Underway, Armed With CV Claim
India’s Trial Approval Timelines Report Card – Some Red Lines?
J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More
J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More
What Does 2017 Hold For Pharma?
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data
Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee
Boehringer/Lilly's Jardiance Wows With CVOT Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel